Sign in
WT

WILLIS TOWERS WATSON PLC (WTW)·Q1 2025 Earnings Summary

Executive Summary

  • Q1 2025 delivered 5% organic growth with material margin expansion (operating margin 19.4%, +740 bps YoY; adjusted operating margin 21.6%, +100 bps YoY), despite reported revenue declining 5% to $2.22B due to the divestiture of TRANZACT .
  • On S&P Global consensus, WTW slightly missed: EPS $3.13 vs $3.19 consensus*, revenue $2.22B vs $2.29B consensus*, while adjusted EBITDA tracked close to expectations (press release $532M vs $535.5M consensus*), with FX a $0.09 EPS headwind expected to unwind by year-end .
  • Segment mix: Risk & Broking sustained high growth (revenue +5% reported, +7% organic; margin 22.0%, +120 bps YoY), while HWC posted +3% organic growth with margin up 160 bps, aided by TRANZACT sale and transformation savings .
  • 2025 framework reiterated: mid-single digit organic growth, annual adjusted operating margin expansion, ~$1.5B buybacks, FX neutral (improved vs Q4 guide) and an EPS headwind from the Bain reinsurance JV of ~$0.25–$0.35; free cash flow margin expected to expand despite transformation cash outflows .

What Went Well and What Went Wrong

  • What Went Well

    • Margin expansion across the enterprise: operating margin 19.4% (+740 bps YoY); adjusted operating margin 21.6% (+100 bps YoY), driven by operating leverage and completed transformation savings .
    • R&B momentum: revenue +5% reported (+7% organic), margin +120 bps to 22.0%; specialty lines and global construction wins highlight the specialization strategy’s effectiveness .
    • Technology and efficiency: rollout of Neuron trading platform (D&O and cyber) and WE DO automation initiatives scaling across 22 countries; management emphasized AI/automation to support productivity and margin expansion .

  • What Went Wrong

    • Consensus miss: EPS $3.13 vs $3.19*, revenue $2.22B vs $2.29B*, as reported revenue declined 5% due to TRANZACT sale; FX was a $0.09 EPS headwind in Q1 (expected to unwind by year-end)* .
    • HWC growth tempered: 3% organic in HWC; Career grew 1% amid client deferrals; Investments face potential near-term volatility impact; BD&O only +1% .
    • Free cash flow negative in Q1 (-$86M) on timing (TRANZACT seasonality and compensation payments), with another headwind expected in Q2 before improving for full year .

Financial Results

MetricQ3 2024Q4 2024Q1 2025
Revenue ($USD Billions)$2.289 $3.035 $2.223
Diluted EPS ($)$(16.44) $12.25 $2.33
Adjusted Diluted EPS ($)$2.93 $8.13 $3.13
Operating Margin %(33.5)% 29.7% 19.4%
Adjusted Operating Margin %18.1% 36.1% 21.6%
Adjusted EBITDA ($USD Millions)$501 $1,173 $532
Adjusted EBITDA Margin %21.9% 38.6% 23.9%
SegmentQ1 2024Q1 2025
HWC Revenue ($USD Millions)$1,336 $1,165
HWC Operating Margin %25.1% 26.7%
R&B Revenue ($USD Millions)$978 $1,027
R&B Operating Margin %20.8% 22.0%
KPIs (Q1 2025)Value
Net Income ($USD Millions)$239
Adjusted Net Income ($USD Millions)$316
Cash from Operations ($USD Millions)$(35)
Free Cash Flow ($USD Millions)$(86)
Adjusted Income Tax Rate %22.7%
Share Repurchases ($USD Millions)$200
Dividends Paid ($USD Millions)$88
Q1 2025 vs ConsensusConsensus*Actual
Primary EPS ($)3.19*3.13
Revenue ($USD Billions)2.29*2.22
EBITDA ($USD Millions)535.54*532 (Adjusted)

Values marked with * retrieved from S&P Global.

Guidance Changes

MetricPeriodPrevious Guidance (Q4 2024)Current (Q1 2025)Change
FX impact on adjusted EPSFY 2025~$(0.18) headwind Neutral at current rates Improved
Share repurchasesFY 2025~$1.5B ~$1.5B (subject to conditions) Maintained
Adjusted operating margin outlookFY 2025+~100 bps avg annual expansion in R&B; incremental at HWC/enterprise Same Maintained
Reinsurance JV EPS impactFY 2025$(0.25)–$(0.35) headwind $(0.25)–$(0.35) headwind Maintained
Tax rateFY 2025~consistent with 2024 (implied)Expect 2025 tax rate relatively consistent with 2024 Maintained
Free cash flowFY 2025FCF margin to expand; transformation cash outflows in 2025 FCF margin expansion; transformation cash outflows and cash taxes on Willis Re earnout Maintained (clarified)

Earnings Call Themes & Trends

TopicQ3 2024 (prior)Q4 2024 (prior)Q1 2025 (current)Trend
AI/technology initiativesICT strength in software; transformation savings supporting margins Emphasis on automation/AI to drive productivity and margins Neuron live trading (D&O/cyber); WE DO automation scaled to 22 countries Increasing adoption
Supply chain/tariffs/macroMacro resilience; specialty growth Continued margin expansion framework Tariff Guard product; global trade/tariff risks; specialty demand resilient Heightened focus
Product performance (specialty & ICT)R&B +10% organic; ICT tech sales strong R&B +7% organic; ICT +11% CRB +8% (ex book & interest); ICT +3% (lumpy) Mixed (still solid)
Regional trendsBroad-based growth across regions (R&B) Global growth in HWC and R&B Double-digit Health outside NA; NA mid-market Health strong Improving ex-NA
Regulatory/legalTransformation program cost/savings Outlook reiterates compliance/AI considerations EU pay transparency; workforce/incentive design demand Rising relevance
HWC mix & sensitivityHWC +4% organic; BD&O moderated HWC +3% organic; BD&O decline (TRANZACT) HWC +3% organic; Career deferrals; BD&O +1% Stable-to-mixed

Management Commentary

  • CEO perspective: “We had a solid start to the year... making strong progress on our strategy to accelerate our performance, enhance our efficiency and optimize our portfolio.”
  • Market environment: “Global trade... new American tariffs... WTW introduced the Tariff Guard endorsement... a strategic enhancement to commercial property coverage for natural resources companies.”
  • Efficiency and tech: “Neuron... connects brokers and insurers in real time... WE DO’s Right Technology strategy... automate critical data audit... scaled to 22 countries.”
  • Outlook confidence: “Confident in delivering mid-single-digit organic growth, adjusted operating margin expansion, adjusted EPS growth and ongoing improvement in free cash flow margin.”

Q&A Highlights

  • HWC growth cadence: Health +6% (double-digit internationally), Wealth +2%, Career +1% (deferrals), BD&O +1%; full-year HWC mid-single-digit growth expected .
  • R&B organic growth: Management targets mid-to-high single digit for 2025; specialization strategy and specialty demand underpin resilience despite tariff/macro uncertainty .
  • Free cash flow trajectory: Q1 FCF -$86M driven by TRANZACT seasonality (-$56M YoY headwind) and compensation; smaller TRANZACT headwind in Q2 (~$8M); full-year FCF margin expected to expand .
  • M&A approach: Focused on targets that improve business mix, expand across the insurance value chain, and enhance margins/FCF; disciplined pacing despite broader broker activity .
  • Buyback pacing: Committed to $1.5B for 2025, pacing opportunistic based on conditions; room to “lean in” at times .
  • ICT lumpy growth: 3% in Q1 after strong Q4 (11%), driven by mix of tech license sales and consulting .

Estimates Context

  • Q1 2025 EPS and revenue were slightly below S&P Global consensus: EPS $3.13 vs $3.19* and revenue $2.22B vs $2.29B*, largely reflecting the TRANZACT divestiture’s impact on reported revenue and a $0.09 FX headwind to EPS that is expected to unwind by year-end .
  • Adjusted EBITDA was close to consensus: press release adjusted EBITDA $532M vs consensus $535.5M* .
  • Implications: Modest estimate trims likely on reported revenue lines (ex-divestiture) and near-term HWC advisory softness, with margins and full-year FCF trajectory supportive for EPS stability.

Values marked with * retrieved from S&P Global.

Key Takeaways for Investors

  • Operating leverage and transformation benefits are flowing through: margin expansion in both segments and at the enterprise level provides cushion against macro and mix headwinds .
  • R&B specialization remains the growth engine; watch specialty demand, pricing and FX (headwind in Q1 but neutral expected for FY), and ICT license cadence .
  • HWC growth steady but mixed: resilient recurring revenue base, with near-term advisory softness; expect Health strength (ex-NA), and seasonal second-half skew in Career .
  • FCF seasonality matters: Q1/Q2 headwinds (TRANZACT timing, compensation) should reverse, supporting full-year buybacks (~$1.5B) and FCF margin expansion .
  • Guidance improved on FX vs Q4: neutral FX outlook, while JV EPS headwind unchanged; execution on margin framework is a key stock narrative driver .
  • Monitor estimate resets: slight Q1 miss vs consensus* suggests modest revisions; margin/FCF visibility and capital returns can anchor the medium-term thesis.
  • Tactical lens: specialty strength, automation/AI initiatives (Neuron, WE DO), and capital discipline (buybacks) are near-term catalysts, while advisory demand normalizes with policy clarity .